EMA Authorised: Crysvita (burosumab) — Kyowa Kirin Holdings B.V.

View source ↗

Summary

The EMA authorised Crysvita (burosumab) for X-linked hypophosphatemia and related familial hypophosphatemia and osteomalacia indications, with orphan designatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypophosphatemia
• Osteomalacia
• X-linked Hypophosphatemia

Drugs mentioned

• Crysvita (burosumab)

Snippet

Status: Authorised. Therapeutic area: Hypophosphatemia, Familial;Hypophosphatemic Rickets, X-Linked Dominant;Osteomalacia. MAH: Kyowa Kirin Holdings B.V.. Decision date: 07/04/2026. Orphan medicine